Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

PHESGO

PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF

Standard Dose
600MG;600MG;20,000UNITS
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PHESGO is listed in Drugs@FDA under application 761170 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF Form and strength INJECTABLE;SUBCUTANEOUS - 600MG;600MG;20,000UNITS Sponsor GENENTECH INC Submission history Latest submission status date: 2024-11-22 00:00:00.

Structured Monograph

Clinical summary

Approval overview PHESGO is listed in Drugs@FDA under application 761170 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF Form and strength INJECTABLE;SUBCUTANEOUS - 600MG;600MG;20,000UNITS Sponsor GENENTECH INC Submission history Latest submission status date: 2024-11-22 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.